Literature DB >> 6423811

Effects of a new aldose reductase inhibitor on various tissues in vitro.

H Terashima, K Hama, R Yamamoto, M Tsuboshima, R Kikkawa, I Hatanaka, Y Shigeta.   

Abstract

A new aldose reductase inhibitor, ONO-2235 [(E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene] rhodanine], was found to possess a potent inhibitory activity of aldose reductase, partially purified from rat lens (IC50 = 1.0 X 10(-8) M) and human placenta (IC50 = 2.6 X 10(-8) M). Against rat lens aldose reductase, ONO-2235 exhibited uncompetitive inhibition as previously observed with 7-hydroxy-4-oxo-4H-chromen-2-carboxylic acid. Sorbitol accumulation in the isolated rat lenses, sciatic nerves and human erythrocytes were all effectively inhibited during incubation with high concentrations of glucose (28-50 mM) by ONO-2235 at a concentration of about 10(-6) M. Because the accumulation of sorbitol has been reported to play an etiological role in the development of diabetic complications, the results suggest that ONO-2235 may prove to be useful in preventing and improving some diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6423811

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Effects of fructose ingestion on sorbitol and fructose 3-phosphate contents of erythrocytes from healthy men.

Authors:  M Kawaguchi; T Fujii; Y Kamiya; J Ito; M Okada; N Sakuma; T Fujinami
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

2.  Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens.

Authors:  A Y Lee; S K Chung; S S Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

3.  Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.

Authors:  H Fujishima; K Tsubota
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

Review 4.  Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.

Authors:  J W Steele; D Faulds; K L Goa
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

5.  Litsea japonica Extract Inhibits Aldose Reductase Activity and Hyperglycemia-Induced Lenticular Sorbitol Accumulation in db/db Mice.

Authors:  Junghyun Kim; Chan-Sik Kim; Eunjin Sohn; Yun Mi Lee; Kyuhyung Jo; Jin Sook Kim
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-23       Impact factor: 2.629

6.  Synthesis and Biological Evaluation of Novel Gigantol Derivatives as Potential Agents in Prevention of Diabetic Cataract.

Authors:  Jie Wu; Chuanjun Lu; Xue Li; Hua Fang; Wencheng Wan; Qiaohong Yang; Xiaosheng Sun; Meiling Wang; Xiaohong Hu; C-Y Oliver Chen; Xiaoyong Wei
Journal:  PLoS One       Date:  2015-10-30       Impact factor: 3.240

7.  Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats.

Authors:  Bai-Bing Yang; Zhi-Wei Hong; Zheng Zhang; Wen Yu; Tao Song; Lei-Lei Zhu; He-Song Jiang; Guo-Tao Chen; Yun Chen; Yu-Tian Dai
Journal:  Int J Impot Res       Date:  2018-09-13       Impact factor: 2.896

8.  Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective.

Authors:  S R Sharma; Nalini Sharma
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.